<DOC>
	<DOCNO>NCT01190176</DOCNO>
	<brief_summary>This study intend provide maximum four year annual oncogenic human papillomavirus ( HPV ) DNA test cervical cytology examination NCT00294047 study subject display normal cervical cytology test positive oncogenic HPV infection conclude NCT00294047 study visit . Women pregnant conclude NCT00294047 study visit may also include study , cervical sample could collect visit . The objective outcome measure primary phase ( NCT00294047 ) present separate protocol posting .</brief_summary>
	<brief_title>Gynaecological Follow-up Subset HPV-015 ( NCT00294047 ) Study Subjects</brief_title>
	<detailed_description>Cervarixâ„¢ control [ Al ( OH ) 3 ] administer primary study NCT00294047 .</detailed_description>
	<criteria>Written inform consent obtain subject prior enrolment . Subjects investigator believe comply requirement protocol . A subject previously enrol study NCT00294047 fulfil either follow criterion : display normal cervical cytology test positive oncogenic HPV infection conclude NCT00294047 study visit pregnant cervical sample could collect conclude NCT00294047 study visit A subject NCT00294047 concluding study visit display normal cervical cytology negative oncogenic HPV infection visit . A subject NCT00294047 concluding study visit cervical lesion visit cervical lesion require treatment NCT00294047 exit colposcopy . A subject cervical cytology result conclude NCT00294047 study visit unavailable reason pregnancy .</criteria>
	<gender>Female</gender>
	<minimum_age>28 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HPV</keyword>
	<keyword>HPV vaccine</keyword>
	<keyword>Cervical neoplasia</keyword>
	<keyword>Human papillomavirus</keyword>
	<keyword>Papillomavirus</keyword>
	<keyword>Cervical cancer</keyword>
	<keyword>Human papillomavirus ( HPV ) type 16/18 infection</keyword>
</DOC>